← Back to Analyst Consensus 
TSHA Buy
Taysha Gene Therapies, Inc.
Current Price —
Implied Upside —
Analysts 19
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 10, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 17, 2026 | Wolfe Research | initiate | — → Outperform | — | 53% |
| Jul 21, 2026 | Goldman Sachs | maintain | Buy → Buy | — | 54% |
| Jul 2, 2026 | Citizens | reiterate | Market Outperform → Market Outperform | — | 47% |
| Jun 30, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jun 30, 2026 | Baird | maintain | Outperform → Outperform | — | 55% |
| Jun 23, 2026 | BMO Capital | maintain | Outperform → Outperform | — | 53% |
| Jun 23, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| Jun 23, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 47% |
| Jun 22, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Apr 6, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Mar 19, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Mar 19, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Mar 3, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Jan 6, 2026 | Chardan Capital | maintain | Buy → Buy | $12 | 47% |
| Jan 5, 2026 | Wells Fargo | maintain | Overweight → Overweight | $11 | 54% |
| Nov 5, 2025 | Citizens | maintain | Market Outperform → Market Outperform | $8 | 47% |
| Nov 5, 2025 | Chardan Capital | maintain | Buy → Buy | $12 | 47% |
| Oct 21, 2025 | Raymond James | initiate | — → Strong Buy | $13 | 54% |
| Oct 17, 2025 | Chardan Capital | maintain | Buy → Buy | $12 | 47% |
| Oct 17, 2025 | Needham | reiterate | Buy → Buy | $10 | 50% |
| Oct 2, 2025 | Baird | maintain | Outperform → Outperform | $12 | 55% |
| Oct 2, 2025 | Needham | maintain | Buy → Buy | $10 | 50% |
| Aug 13, 2025 | Wells Fargo | maintain | Overweight → Overweight | $8 | 54% |
| Aug 13, 2025 | Canaccord Genuity | maintain | Buy → Buy | $14 | 48% |
| Aug 12, 2025 | Chardan Capital | maintain | Buy → Buy | $10 | 47% |
| Jul 11, 2025 | B of A Securities | initiate | — → Buy | $8 | 53% |
| Jul 1, 2025 | Needham | reiterate | Buy → Buy | $8 | 50% |
| Jun 10, 2025 | Needham | reiterate | Buy → Buy | $8 | 50% |
| Jun 3, 2025 | Canaccord Genuity | maintain | Buy → Buy | $11 | 48% |
| Jun 2, 2025 | Needham | reiterate | Buy → Buy | $8 | 50% |
| May 29, 2025 | JMP Securities | maintain | Market Outperform → Market Outperform | $6 | 53% |
| May 29, 2025 | Chardan Capital | maintain | Buy → Buy | $9 | 47% |
| May 16, 2025 | Canaccord Genuity | maintain | Buy → Buy | $9 | 48% |
| Apr 28, 2025 | JMP Securities | reiterate | Market Outperform → Market Outperform | $5 | 53% |
| Apr 28, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $7 | 50% |
| Apr 10, 2025 | Needham | reiterate | Buy → Buy | $6 | 50% |
| Feb 27, 2025 | Needham | reiterate | Buy → Buy | $6 | 50% |
| Feb 26, 2025 | Chardan Capital | maintain | Buy → Buy | $7 | 47% |
| Jan 6, 2025 | Needham | reiterate | Buy → Buy | $6 | 50% |
| Nov 15, 2024 | Canaccord Genuity | maintain | Buy → Buy | $8 | 48% |
| Nov 14, 2024 | Chardan Capital | maintain | Buy → Buy | $7 | 47% |
| Nov 14, 2024 | Needham | reiterate | Buy → Buy | $6 | 50% |
| Nov 14, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $7 | 50% |
| Nov 12, 2024 | JMP Securities | reiterate | Market Outperform → Market Outperform | $5 | 53% |
| Nov 12, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $7 | 50% |
| Nov 12, 2024 | Needham | reiterate | Buy → Buy | $6 | 50% |
| Aug 14, 2024 | Canaccord Genuity | maintain | Buy → Buy | $6 | 48% |
| Aug 13, 2024 | Chardan Capital | maintain | Buy → Buy | $7 | 47% |
| Aug 12, 2024 | Needham | maintain | Buy → Buy | $6 | 50% |
| Jul 26, 2024 | Needham | reiterate | Buy → Buy | $7 | 50% |
Price Target Trend
Apr 10, 2026 Oct 26, 2026
EPS Estimates
+1y —
0q —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days